About Pharmerit_WPadmin

This author has not yet filled in any details.
So far Pharmerit_WPadmin has created 221 blog entries.

Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada.

Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. Objectives To estimate the cost-utility of two trabecular micro-bypass stents (TBS) implantation versus standard of [...]

2019-01-28T09:28:22-04:00January 28th, 2019|

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. Background and Objective Teriflunomide is a once-daily oral immunomodulatory agent approved in 80 countries for the [...]

2019-01-29T10:49:13-04:00January 28th, 2019|

Deep-vein thrombosis in Europe – Burden of illness in relationship to healthcare resource utilization and return to work.

Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Objective Deep-vein thrombosis (DVT) forms a major healthcare burden in Europe, but [...]

2019-01-28T07:33:58-04:00January 22nd, 2019|

Pulmonary embolism in Europe – Burden of illness in relationship to healthcare resource utilization and return to work

Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Objective Pulmonary embolism (PE) is associated with a substantial economic burden. However [...]

2019-01-22T09:25:43-04:00January 22nd, 2019|

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States Objective To evaluate the cost-effectiveness of alemtuzumab compared with fingolimod, natalizumab, ocrelizumab, and generic [...]

2018-12-14T07:23:51-04:00December 14th, 2018|

Key Elements of a Real-World Evidence Generation Plan: Integration of Product Support Activities

Key Elements of a Real-World Evidence Generation Plan: Integration of Product Support Activities Written by: Shelby Corman Real-world evidence is a key component of value demonstration for pharmaceuticals, diagnostic agents, and medical devices throughout the product lifecycle. Planning for [...]

2019-03-19T12:58:09-04:00November 29th, 2018|

Extrapolation in Survival Analysis: What? Why? How? Where next?

Extrapolation in Survival Analysis: What? Why? How? Where next? Survival analysis plays a key role in many cost-effectiveness analyses, particularly those involving products in oncology. During this webinar, presenters will provide an introduction to survival analysis, demonstrate why extrapolation [...]

2019-03-19T12:58:55-04:00October 29th, 2018|